DANIEL MEAD: Open Payments
NPI 1225593726 · FARMINGTON HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,181 in 79 payments from 15 companies in 2025. Trend: 2023 $894 · 2024 $278 · 2025 $2,181
Food & beverage: $1,960Education: $221
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $403 |
| Otsuka America Pharmaceutical, Inc. | 11 | $403 |
| Neurocrine BioSciences, Inc. | 18 | $362 |
| Lundbeck LLC | 8 | $233 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $212 |
| Axsome Therapeutics, Inc. | 4 | $111 |
| Alkermes, Inc. | 4 | $109 |
| Corium, LLC | 3 | $94 |
| Vanda Pharmaceuticals Inc. | 2 | $69 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
Products named: REXULTI, INGREZZA, CAPLYTA, Auvelity, ARISTADA, Azstarys, UZEDY, AUSTEDO XR.
Industry payments across MI — which companies pay providers there.
